{"id":"voglibose-basen","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances (flatulence, diarrhea, abdominal discomfort)"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting enzymes (alpha-glucosidase) that break down disaccharides and complex carbohydrates, voglibose delays glucose absorption and flattens the postprandial glucose curve. This reduces peak blood glucose excursions after meals in patients with type 2 diabetes without stimulating insulin secretion directly.","oneSentence":"Voglibose is an alpha-glucosidase inhibitor that slows the digestion and absorption of carbohydrates in the small intestine, reducing postprandial blood glucose levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:15:41.499Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01242202","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-21","conditions":"Type 2 Diabetes Mellitus","enrollment":113},{"nctId":"NCT05688332","phase":"PHASE3","title":"Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients","status":"UNKNOWN","sponsor":"University of Zambia","startDate":"2023-08","conditions":"Diabetes Mellitus Type 2 Without Complication","enrollment":118},{"nctId":"NCT01309698","phase":"PHASE4","title":"Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-02","conditions":"Type 2 Diabetes","enrollment":24},{"nctId":"NCT02049814","phase":"PHASE4","title":"Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-05-09","conditions":"Type 2 Diabetes Mellitus","enrollment":494},{"nctId":"NCT01993927","phase":"","title":"Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance \"Long-term Use in Patients With Impaired Glucose Tolerance\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-11-18","conditions":"Impaired Glucose Tolerance","enrollment":742},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":585},{"nctId":"NCT00212017","phase":"NA","title":"Assessment of an Alpha-glucosidase Inhibitor to Block Cardiac Events in Patients With MI and IGT","status":"TERMINATED","sponsor":"National Cerebral and Cardiovascular Center, Japan","startDate":"2005-04","conditions":"Impaired Glucose Tolerance, Myocardial Infarction","enrollment":3000},{"nctId":"NCT00837577","phase":"PHASE3","title":"MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02-05","conditions":"Diabetes Mellitus, Non-Insulin-Dependent","enrollment":133},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":886172},{"nctId":"NCT00411554","phase":"PHASE3","title":"A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01","conditions":"Diabetes Mellitus, Non-Insulin-Dependent","enrollment":319},{"nctId":"NCT02287402","phase":"PHASE4","title":"Postmarketing Clinical Study on AO-128","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-03","conditions":"Impaired Glucose Tolerance (IGT)","enrollment":197},{"nctId":"NCT02097342","phase":"PHASE4","title":"Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2013-12","conditions":"Type 2 Diabetes Mellitus, Insulin Sensitivity/Resistance","enrollment":30},{"nctId":"NCT00970528","phase":"PHASE4","title":"Glucose Reduction by Early Acarbose Treatment in Basal Insulin","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-11","conditions":"Diabetes Mellitus, Type 2","enrollment":124},{"nctId":"NCT00654381","phase":"PHASE3","title":"Japanese P III vs Voglibose and Placebo","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-04","conditions":"Diabetes Mellitus, Type 2","enrollment":561},{"nctId":"NCT00663884","phase":"PHASE4","title":"Glufast On Insulin Glargine Trial in Type 2 DM","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2008-02","conditions":"Diabetes Mellitus, Type 2","enrollment":167},{"nctId":"NCT01263483","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-01","conditions":"Type 2 Diabetes Mellitus","enrollment":230},{"nctId":"NCT01263470","phase":"PHASE2","title":"Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-01","conditions":"Diabetes Mellitus, Type 2","enrollment":480},{"nctId":"NCT01263509","phase":"PHASE2, PHASE3","title":"Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-06","conditions":"Type 2 Diabetes Mellitus","enrollment":179},{"nctId":"NCT01263496","phase":"PHASE2","title":"Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-05","conditions":"Type 2 Diabetes Mellitus","enrollment":438},{"nctId":"NCT01055652","phase":"PHASE1","title":"Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-01","conditions":"Type 2 Diabetes Mellitus","enrollment":28},{"nctId":"NCT00724542","phase":"NA","title":"Evaluation of Intervention on Impaired Glucose Tolerance(IGT) in Patients With Coronary Heart Disease.","status":"UNKNOWN","sponsor":"Ministry of Science and Technology of the People´s Republic of China","startDate":"2008-07","conditions":"Coronary Heart Disease, Impaired Glucose Tolerance","enrollment":1600},{"nctId":"NCT00368134","phase":"PHASE3","title":"To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-08","conditions":"Diabetes Mellitus, Type 2","enrollment":370}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Voglibose (Basen)","genericName":"Voglibose (Basen)","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Voglibose is an alpha-glucosidase inhibitor that slows the digestion and absorption of carbohydrates in the small intestine, reducing postprandial blood glucose levels. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}